Interferon-γ liposome: a new system to improve drug delivery in the treatment of lung cancer

Maysa Alhawamdeh, Mohammad Isreb, Abid Aziz, Badie K. Jacob, Diana Anderson, Mojgan Najafzadeh
ERJ Open Research 2021 7: 00555-2020; DOI: 10.1183/23120541.00555-2020

This article has a correction. Please see:

Abstract

Lung cancer is one of the main causes of death worldwide. Published data show the use of interferons (IFNs) in treating lung tumours. IFNs also have potential for their antiproliferative, antiangiogenic, immunoregulatory and proapoptotic effects. IFN-γ functions as an anticancer agent against various forms of cancer. This study aimed to investigate the effect of IFN-γ liposome (nano) on peripheral lymphocytes from 20 individuals in each group: lung cancer patients compared to healthy individuals. The effectiveness of IFN-γ liposome against oxidative stress was also evaluated in this study. A concentration of 100 U·mL−1 of IFN-γ liposome was used to treat the lymphocytes in the Comet and micronucleus assays based on the preliminary test for the optimal dose. The lymphocytes from lung cancer patients presented with higher DNA damage levels than those of healthy individuals. In healthy individuals, IFN-γ liposome did not cause any DNA damage in the lymphocytes. Also, it caused a significant reduction in DNA damage in the lymphocytes from lung cancer patients in both the Comet and micronucleus assays. The 100 U·mL−1 of IFN-γ liposome significantly reduced the oxidative stress caused by H2O2 and appeared to be effective in both groups using the Comet and micronucleus assays. Results from both Comet and micronucleus assays were consistent. The data obtained indicated that IFN-γ in both forms (IFN-γ bulk and IFN-γ nanoliposome) may potentially be effective for the treatment of lung cancer and showed the ability of IFN-γ liposome to reduce DNA damage more than the bulk form.

Abstract

A research article on the effect of bulk and nanoliposome interferon-γ on lymphocytes from patients with lung cancer compared to healthy controls: assessing the ability of IFN-γ liposome to reduce DNA damage more than the bulk form https://bit.ly/3wvfSyY

Introduction

The term lung cancer encompasses epithelial cancers in the mucosa of the bronchi and sometimes in the parenchyma of the lung, which exists in the trachea (windpipe), bronchi (airways) or lung air sacs (alveoli) [1, 2]. Lung cancer accounts for roughly 13% of annual cancer cases worldwide. It is also the second most common type of cancer in both males and females within the UK, although its incidence is higher in males than females [3]. In the UK, lung cancer is the leading reason for cancer death, with approximately 35 000 deaths annually. The diagnostic peaks for lung cancer are between the ages of 73 and 84 years [4], and the overall 5-year survival rate is less than 10%, mainly because the majority of patients present with a late phase of the disease, a point at which treatment has little impact on survival [5]. This cancer could be developed or extended to the airways, resulting in symptoms such as cough, airway obstruction and haemoptysis. The tumour can metastasise to the thorax area, causing compression. It might also invade the chest wall and extend further, via the hilar, mediastinal and supraclavicular nodes [6]. Furthermore, it enhances transformations in the central or peripheral nervous system, leading to anorexia and causing a disturbance in hormone production. Cancer metastasises via the blood to different parts of the body, specifically to the liver, brain, adrenal gland and axial skeleton [7].

Studies have shown that cigarette smoking is the main risk factor in lung cancer patients. Current smokers have a 15-fold increase in risk of death from lung cancer compared with lifelong nonsmokers [8]. On the other hand, this risk decreases significantly in individuals who cease smoking before middle age [9]. The risk of lung cancer is also elevated following exposure to environmental tobacco smoke (ETS). An estimated 14–15% of lung cancers are caused by exposure to ETS [10]. 85% of lung cancer patients have nonsmall cell lung cancer (NSCLC), including adenocarcinoma, adenosquamous cell carcinoma, squamous cell carcinoma and large cell carcinoma.

IFN-γ is produced mainly by Th1 CD4+ T cells, CD8+ T cells and natural killer (NK) cells. Additionally, recent studies have indicated that other cells such as B cells, natural killer T (NKT) cells and professional antigen-presenting cells (APCs) may also be a source of IFN-γ. This secretion is controlled primarily by IL-12 and IL-18 [11]. IFN-γ has major antiviral, immunoregulatory and antitumour roles, through interaction with specific cell-surface receptors, including four transmembrane polypeptide receptor complexes: two ligand-binding chains (IFN-γR1) and two signal-transducing chains (IFN-γR2), which are required for signal transduction [12]. The most critical transduction pathway stimulated by IFN-γ is the Janus kinase (Jak)/signal transducer and activator of transcription 1 (STAT1) pathway. This contributes to the antiproliferative effects of IFN-γ on different cell types, as it has been elucidated that both pathways have the potential to inhibit tumour progression and kill pathogen-infected cells [13]. This is done by binding two IFN-γ R2 subunits with two IFN-γ-bound IFN-γ R1 chains [14]. After the receptor complex association is induced, Jak1 and Jak2 activate and phosphorylate Tyr440 of IFN-γ R1, forming a docking site for STAT1. STAT1 is activated by phosphorylation at Tyr701, leading to homodimerisation of STAT1 and nuclear translocation. The STAT1 dimers interact with specific DNA sequences called IFN-γ-activated sequences (GAS), present in the promoter regions of IFN-stimulated genes, and responsible for regulating their transcription [15, 16]. The entirety of these mechanisms are presented in figure 1 [17].

FIGURE 1
FIGURE 1

Per cent survival in 10 × 104 cells of various test treatments in lymphocytes from healthy individuals and lung cancer patients using CCK-8 assay. Error bars show mean values±se, n=3. NC: nucleated cell; PC: positive control; IFN: interferon; ns: nonsignificant. *: p<0.05; **: p<0.01; ***: p<0.001.

The transcriptional activity of STAT1 is stimulated through kinases. These kinases are mitogen-activated protein kinase (MAPK), protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)/AKT, which phosphorylates STAT1 in the transactivation domain [17]. The mechanism of the STAT1 pathway plays a positive role by regulating the expression of genes encoding several antiproliferative and proapoptotic molecules, such as IFN regulatory factor 1 (IRF-1). However, if IRF-1 is inhibited, the IFN-γ activates the proliferative signals. On the other hand, when the IRF-1 is elevated, the IFN-γ stimulates apoptotic signals [18, 19]. In mice, those with deficient IFN-γ spontaneously develop lung epithelial malignancies and lymphoma. Furthermore, mice with a deficient IFN-γ receptor and STAT1 manifest tumour growth following chemical carcinogen treatment, which emphasises the ability of IFN-γ to act as an anticancer agent [20]. Furthermore, preliminary research indicates that IFN-γ, given as a single agent, has a measurable effect as an antitumour agent in advanced NSCLC [21].

Liposomes are artificial vesicles made from single or multiple phospholipid layers (lamellas) with spherical, self-assembled shapes. Their sizes typically range from tens of nanometres up to hundreds of micrometres, depending on their preparation methods [22, 23]. They can also be made from nontoxic surfactants, cholesterols and membrane proteins [24]. Liposomes have been used extensively as drug delivery carriers and utilised for biomedical and biotechnological purposes [25]. The encapsulation of the drug into liposomes can reduce the toxicity, enhance the pharmacokinetics of the drug and result in more efficient therapeutic effects [26].

Moreover, liposomes can increase bioavailability and improve the solubility of poorly water-soluble drugs [5]. A recent study adopted the IFN-γ liposome-based drug delivery method by modifying it with cyclic peptides in order to initiate an antifibrotic effect for the therapy of hepatic fibrosis in the rat. It was found that the sterically modified IFN-γ liposomes have a greater antifibrotic effect of activating the hepatic stellate cells by 7.24-fold and 2.95-fold compared to free IFN-γ, with fewer adverse side-effects [27].

The primary objective of this research was to study the DNA protective effect of IFN-γ bulk and IFN-γ liposome on lymphocytes from lung cancer patients compared to healthy individuals.

In this study, the effect of IFN-γ bulk and IFN-γ liposome on DNA damage was detected in peripheral blood lymphocytes of lung cancer patients and healthy individuals by using the Comet micronucleus assay. The Comet assay was used in this study due to its sensitivity and simplicity for analysis of the genotoxicity of DNA in lymphocytes as presented in previous studies [28–30].

Materials and methods

Materials

IFN-γ (≥98% purity; Cat No. 17001), Mitomycin C (MMC) (Cat No. M0503) and fetal bovine serum (FBS) (Cat No. F7524) were purchased from Sigma-Aldrich (Gillingham, UK). RPMI 1640 Medium (RPMI-1640) (Cat No. R8758), phytohaemagglutinin (PHA) (Cat No. L1668) and penicillin–streptomycin solution (Cat No. P4333) were also obtained from Sigma-Aldrich. All other chemicals used in the different tests were from Sigma-Aldrich Company Ltd. (Sigma Chemical Ltd., Gillingham, UK). Prior to using the IFN-γ, the lyophilised powder was reconstituted in double distilled water to form the stock solution. It was then diluted in RPMI-1640 Medium with 10% FBS and stored at −20°C.

The dose–response experiments were carried out to determine the optimal doses of IFN-γ bulk and liposome and H2O2 used throughout the study. A fixed dose of both forms (100 U·mL−1 of IFN-γ bulk and 100 U·mL−1 of IFN-γ liposome) were used as treatment. The classic genotoxic compound hydrogen peroxide (H2O2) (75 μM) was used as a positive control (PC).

Preparation and characterisation of liposomes

Liposomes were prepared using the thin film rehydration method. 1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol were dissolved in dichloromethane (DCM) and methanol (3:1 v/v). The solution was then transferred to a rotary evaporator with a 25 mL round-bottomed flask. The organic solvent mixture was evaporated at 40°C under vacuum for 6 h, to ensure no traces of the organic solvents were left. The thin film was then hydrated by 10 mL of PBS solution of IFN-γ for 1 h at 60°C using a bath sonicator (150 W). The sample was then subjected to four repeated freeze–thaw cycles (freezing at −20°C and thawing at 60°C in the bath sonicator). Furthermore, the blank liposome was prepared from the same components without adding the IFN-γ.

Average size and polydispersity index (PDI) of the liposome preparations were determined by dynamic light scattering (DLS) using Zetasizer ZS (Malvern Instruments, UK). All measurements were performed in triplicate.

Ethical approval

Ethical approval was obtained to execute the Comet and micronucleus assays for the study of IFN-γ and IFN-γ liposome. This study received ethical approval from Leeds East Research Ethics Committee (REC number: 12/YH/0464), the University of Bradford Research Ethics Sub-Committee on Research in Human Subjects (Ref: 0405/8) and the Research Support and Governance Office, Bradford Teaching Hospitals, NHS Foundation (Ref: RE DA 1202).

Sample preparation and Comet assay

After obtaining consent from healthy nonsmoking volunteers and lung cancer patients, whole blood samples were collected by venepuncture in 9 mL lithium heparin-coated tubes and clearly labelled for ease of identification. Samples were diluted in a ratio of 1:1 with RPMI-1640 Medium, and then mixed with 10% dimethyl sulfoxide (DMSO). The diluted blood solution was divided and transferred to labelled 1.5 mL Eppendorf® tubes, which were closed tightly and stored at −80°C.

The Comet assay was prepared according to [31, 32]. In brief, 100 μL of whole blood samples were incubated for 30 min at 37°C with different test agents, to make the final volume of 1000 μL with RPMI-1640 Medium (with sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell culture). The test agents included a PC of 75 μM H2O2, blank liposome IFN-γ 100 U·mL−1 and IFN-γ liposome in order to test the effect of IFN-γ in a highly oxidising environment; 100 U·mL−1 of IFN-γ and IFN-γ liposome were treated in the presence of 75 mM H2O2. An untreated sample was used as a negative control. The samples were then incubated at 37°C for 30 min. Following incubation, the samples were centrifuged at 3000 rpm for 5 min. The method used thereafter was followed as described in [28–30].

The slides were coded before scoring; per slide, 100 nuclei were scored using a fluorescent microscope at 20× magnification. This was connected to a CCD camera using Komet 6 software and Kinetic Imaging (Andor Technology Ltd, Belfast). Olive tail moment (OTM) and % tail DNA were used simultaneously to decrease variability in the results [33].

The cytokinesis block micronucleus (CBMN) assay

Whole blood (500 μL) was added to a T25 cm2 Corning culture flask containing 4.5 mL RPMI-1640 Medium supplemented with 1% penicillin–streptomycin, 15% FBS and 25 mM HEPES and L-glutamine with end concentrations of 15% and 1%, respectively, followed by 100 μL of phythaemagglutinin (PHA) (2.5%). In the next 24 h, 50 μL of blank liposome was added to the negative control. Two positive controls were used with 10 μL of MMC (0.4 μM) used as PC 1, and 50 μL of H2O2 served as PC 2. 50 μL of 100 U·mL−1 IFN-γ and IFN-γ liposome were added to their respective flasks and the final flask contained IFN-γ liposome and H2O2. 50 μL of cytochalasin-B (6 μg·mL−1, Sigma) was added to each flask and cultured at 37°C in the presence of 5% CO2 for 44 h. The CBMN procedures were performed as described by Fenech and coworkers [34, 35].

Numerous cytological scoring parameters were used to assess DNA damage. Micronuclei (MNi) were scored from both binucleated cells (BiNCs) and mononucleated cells (MonoNCs). Nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) were only scored for BiNC [36]. The nuclear division index (NDI) was calculated using the equation NDI=M1+2(M2)+3(M3)/N, where M1=mononucleated cells, M2=binucleated cells, M3=multinucleated cells and N=total number of viable cells scored [35].

Cell viability

The viability of cells was detected after 30 min of incubation of cells with different concentrations of treatments. Lymphocytes were isolated from whole blood using ficoll-paque as described in [37]. Cell viability was then determined by the trypan blue staining method described in [38] and the Cell Counting Kit-8 (CCK-8) method [39]. The concentrations with cell viability of ≥75% were used in all experiments [40].

Statistical analysis

The final data were expressed as mean values with standard errors, the results were analysed using one-way ANOVA with Dunnett's multiple comparisons test using GraphPad Prism 8.1.2. p-values were considered significant at p<0.05, p<0.01, p<0.001.

Results

The viability of lymphocytes from healthy individuals and lung cancer patients was assessed after treatment with chemicals used in this study was between 75% and 85% using trypan blue dye exclusion. The viability of lymphocytes from healthy individuals and lung cancer patients treated with different treatment groups was also confirmed using the CCK-8 assay ≥75 after 24 h treatment (figure 1).

Comet assay: IFN-γ liposome versus bulk

The data from the Comet assay results showed that lung cancer patient lymphocytes were more susceptible to DNA damage than healthy individuals, in % tail DNA and OTM, when compared with groups that received no treatment (p<0.001) as presented in table 1, figures 2 and 3. A significant increase in % tail DNA and OTM in lymphocytes from healthy volunteers and lung cancer patients after exposure to PC (75 μM H2O2) (p≤0.001) (figures 2 and 3).

View this table:
TABLE 1

The mean values of experiments on blood samples from 20 healthy individuals and 20 lung cancer patients expressed as OTM and % tail DNA

FIGURE 2
FIGURE 2

DNA damage measured as mean olive tail moment before and after treatment with bulk and liposome forms of interferon (IFN)-γ in human lymphocytes from healthy individuals and lung cancer patients in the Comet assay. n=20 in each group. NC: nucleated cells; PC: positive control; ns: nonsignificant. *: p<0.05; **: p<0.01; ***: p<0.001.

FIGURE 3
FIGURE 3

DNA damage measured as mean % tail DNA before and after treatment with bulk and liposome forms of interferon (IFN)-γ in human lymphocytes from healthy individuals and lung cancer patients in the Comet assay. n=20 in each group. NC: nucleated cells; PC: positive control; ns: nonsignificant. *: p<0.05; **: p<0.01; ***: p<0.001.

Lymphocytes obtained from 20 healthy individuals (figures 2 and 3) showed that 100 U·mL−1 IFN-γ bulk and IFN-γ liposome was clearly unaffected in lymphocyte cells when measuring % tail DNA and OTM compared to untreated cells. In contrast, the H2O2-induced DNA damage was significantly reduced by 100 U·mL−1 IFN-γ bulk and IFN-γ liposome in lymphocytes from healthy individuals compared to the PC (75 μM H2O2) (p≤0.001). In contrast, IFN-γ liposome was more effective in reducing the DNA damage than IFN-γ bulk, as presented in table 1.

Lymphocytes from lung cancer patients (n=20) also showed a significant decrease in % tail DNA and OTM from 10.97% (% tail DNA) and 2.18 (OTM) compared to the untreated control groups to 8.42% (% tail DNA) and 1.38 (OTM), respectively, when cells were treated with IFN-γ bulk whereas the reduction in % tail DNA and OTM was more effective by using IFN-γ liposome, which showed a significant decrease in % tail DNA 6.65% and 1.07 (OTM). Furthermore, cells treated with IFN-γ bulk and IFN-γ liposome co-supplemented with 75 μM H2O2 showed significant decreases in OTM and % tail DNA compared to the PC (75 μM H2O2) (p≤0.001).

CBMN: effect of IFN-γ liposome

The lymphocytes from healthy individuals and lung cancer patients were treated with 75 μM H2O2, 0.4 μM MMC, 100 U·mL−1 of IFN-γ bulk, IFN-γ liposome and 100 U·mL−1 of IFN-γ bulk, IFN-γ liposome with 75 μM H2O2. They were then assessed for MNi induction using the CBMN assay, as presented in figure 4. In contrast, lymphocytes from healthy individuals treated with 100 U·mL−1 of IFN-γ bulk and IFN-γ liposome showed no effect on MNi frequency compared to untreated cells. The MMC and 75 μM H2O2 displayed a significant increase in the MNis of lymphocytes (p<0.001), but 100 U·mL−1 of IFN-γ bulk and IFN-γ liposome co-supplemented with H2O2 showed a significant decrease in MNis of lymphocytes (p<0.05) as in figure 4. It was evident that the 100 U·mL−1 of IFN-γ bulk and IFN-γ liposome showed a significant reduction in the number of MNis in lung cancer patients, but the reduction by IFN-γ liposome was greater (p<0.001) compared to untreated cells. Furthermore, the MMC and 75 μM H2O2 showed a significant increase (p<0.001) in the MNi number on lymphocytes compared to the untreated cells.

FIGURE 4
FIGURE 4

Comparison of MNi frequencies between healthy individuals and lung cancer patients, after treatment with 75 μM H2O2, 0.4 μM Mitomycin C (MMC), 100 U·mL−1 of interferon (IFN)-γ bulk, IFN-γ liposome and 100 U·mL−1 of IFN-γ bulk, IFN-γ liposome in the presence of 75 μM H2O2. n=5 in each group. BiNC: binucleated cells; NC: nucleated cells; PC: positive control; ns: nonsignificant. *: p<0.05; **: p<0.01; ***: p<0.001.

There are numerous cytological scoring parameters, including biomarkers of cell mitotic division such as mononucleated cells (MoNCs), binucleated cells (BiNCs) and multinucleated cells (MultiNCs). From these parameter values, the NDI was calculated for healthy individuals and lung cancer patients, respectively. The mean values for the NDI for all treatment groups were within the normal range, as shown in table 2. Table 2 also displays the chromosomal instability parameters in the form of the mean of NPBs, NBUDs per 1000 BiNC and MNi frequency in MoNC. The table clearly shows that the frequency of MNi in BiNC of untreated cells is higher than in lymphocytes treated with IFN-γ liposome on lung cancer patients.

View this table:
TABLE 2

The mean of different parameters for chromosomal damage in healthy individuals and lung cancer patients lymphocyte using the cytokinesis block micronucleus assay

Discussion

This study investigated the efficacy of IFN-γ and IFN-γ liposome in human lymphocytes originating from groups of 20 healthy individuals and 20 lung cancer patients, using the Comet assay and five individuals in each group for the CBMN assay. Different in vitro and in vivo studies have shown the promising applications of IFN-γ in the field of health as a treatment displaying pleiotropic immunomodulatory, antiviral, antimicrobial, antineoplastic, proinflammatroy activities [12]. Furthermore, the potent inhibitory effects of IFN-γ in various tumour models, such as bladder carcinoma, colorectal cancer, ovarian cancer, and adult T cell leukaemia, human pancreatic carcinoma cells, and NSCLC have been evidenced [11, 17].

Research has demonstrated that IFN-γ can induce apoptosis in human glioblastoma T98G and U87MG cells [41], and inhibited the proliferation of four pancreatic cancer cell lines in vitro [42]. Other studies indicated that IFN-γ was responsible for apoptosis in ovarian cancer cells in vivo and in vitro [43]. By contrast, none of the previous studies has focused on the effect of IFN-γ on DNA damage in human lymphocytes from lung cancer patients through the use of the Comet and CBMN assay.

The obtained results showed that the treated lymphocytes from healthy individuals with IFN-γ bulk and IFN-γ liposome did not induce significant DNA damage when compared to the untreated cells. However, when the same concentration of IFN-γ in both forms was used on lung cancer patients' lymphocytes, DNA damage was reduced compared to the untreated cells. Still, the reduction of DNA damage that occurred by the liposome form of IFN-γ was greater than from the IFN-γ bulk (figures 2 and 3). This could possibly be due to the biocompatibility and enhanced cellular interaction of liposomes compared to their larger particles [44]. The Comet assay results showed that IFN-γ bulk and the liposome form have a protective effect against H2O2, which induces damage in DNA due to oxidative stress in healthy individuals and lung cancer patients’ lymphocytes. DNA damage significantly decreased compared to the PC. The effective results of IFN-γ liposome against H2O2-induced damage could be due to the ability of liposome in preventing cell membrane alterations rather than its direct interaction with H2O2 [45].

The micronucleus assay was used to investigate the influence of IFN-γ bulk and liposome on the lymphocytes from healthy individuals and lung cancer patients at the chromosomal level. The CBMN assay has been a critical test in detection of the genotoxicity of different compounds by measuring MNi and other chromosomal abnormalities such as NPBs, a biomarker of dicentric chromosomes, and by measuring NBUDs, which are a biomarker of gene amplification [46]. MNis are cytoplasmic bodies generated as a consequence of disorders during cell cycle division. Subsequently, when the centric fragments or whole chromosomes are incapable of travelling to opposite poles during anaphase, the nuclear envelope forms around the lagging chromosomes and fragments, which gradually take on the morphology of an interphase nucleus, which is smaller than the main nuclei in the cell [36, 47]. In this assay, the dividing cell cytokinesis is inhibited with cytochalasin B (Cyto B) [48].

In this study, amongst the different types of cells counted, specific consideration was made for the presence of MNi in the treatment groups because MNi are indicators of chromosomal breakage, loss, rearrangement, necrosis and apoptosis [35]. Furthermore, MNi in BiNC only showed the damage after treatment, which decreased the probability of scoring the pre-existing damage [49]. Mitomycin C (MMC) is recognised as an antitumour antibiotic, clastogenic and genotoxic compound. Therefore, MMC served as a PC in this study. MMC induced MNi production in BiNCs more than mononucleated cells (table 2). The percentage of BiNC after scoring 1000 cells was within the normal range in lymphocyte cultures for each individual. On the other hand, the percentage of MultiNC in cell culture was low, thus elucidating that cytochalasin B inhibited cell division after one cell cycle. Meanwhile, the NDI values were normal for all experiments (table 2).

From this assay, the frequency of MNi in the lymphocytes from healthy individuals and lung cancer patients decreased when treated with IFN-γ and IFN-γ liposome compared to the untreated cells (NC) for each group. In contrast, the IFN-γ liposome showed a greater reduction in MNi frequency in lymphocytes. H2O2 was used in this assay and functioned as expected, inducing MNi production on the lymphocytes from both healthy individuals and lung cancer patients. The combination of IFN-γ bulk and IFN-γ liposome with H2O2 reduced the frequency of MNis compared to H2O2 in patients’ lymphocytes. This study's most important finding was that IFN-γ liposome had exhibited higher DNA damage reduction effects at 100 U·mL−1 concentration than IFN-γ bulk.

The Comet assay data showed that IFN-γ in bulk and liposome form reduced DNA damage in the lymphocytes from healthy individuals and lung cancer patients compared to the NC.

Our results were consistent with a previous study where IFN-γ induced early stimulation of PARP (the DNA repair enzyme) when the cells were exposed to a proapoptotic agent [50]. Furthermore, DNA damage was decreased when the IFN-γ bulk and liposome were treated with H2O2 in the lymphocytes from healthy individuals and lung cancer patients compared to the PC. This denotes the ability of IFN-γ to protect against DNA damage in lymphocytes from oxidative stress. The CBMN assay followed a similar pattern to the Comet assay results. It also showed a reduction in MNi frequency in the lymphocytes, thus implying the potential facilitation of DNA repair.

In general, IFN-γ liposome (100 U·mL−1) has shown better protective effects than its larger particle counterpart, bulk, at the same concentrations of 100 U·mL−1 each. This could perhaps be due to the enhanced solubility of liposome-coated IFN-γ in an aqueous medium stabilising various therapeutic agents such as proteins and nucleotides. Their size, surface charge and composition are favourable conditions for their effective results [51]. Many hydrophilic and hydrophobic biomolecules can be encapsulated in liposomes and protected from interactions with the external environment. Liposomes inhibit the metabolism of the drug before reaching the target cells plus protect the drug's interaction with healthy cells, enhancing the therapeutic index of the drug. It has been well documented that the liposome form of any therapeutic drug shows enhanced pharmacokinetic properties and biodistribution than its free form. The morphology of liposomes is similar to that of the cellular membranes, making them an ideal drug carrier system [44].

In conclusion, the data obtained from the Comet and micronucleus assays indicated that IFN-γ in both forms might potentially be effective for lung cancer patients. Overall data from the present study proposes that IFN-γ could protect and defend against lung cancer through cell cycle arrest of cancer cells and repair mechanisms and liposomes can potentially be used as an alternative, better drug delivery system in various conditions.

Acknowledgement

The authors would like to thank the clinical staff of Bradford Royal Infirmary and St Luke's Hospital for their assistance in this study.

Footnotes

  • This article has been revised according to the author correction published in ERJ Open Res 2021; 7: 50555-2020 [https://doi.org/10.1183/23120541.50555-2020].

  • Conflict of interest: M. Alhawmdeh has nothing to disclose.

  • Conflict of interest: M. Isreb has nothing to disclose.

  • Conflict of interest: A. Aziz has nothing to disclose.

  • Conflict of interest: B.K. Jacob has nothing to disclose.

  • Conflict of interest: D. Anderson has nothing to disclose.

  • Conflict of interest: M. Najafzadeh has nothing to disclose.

  • Support Statement: The sponsorship by the Mutah University of a PhD studentship to Maysa Alhawamdeh is gratefully acknowledged. The sponsor played no part in the conduct of the work or the writing of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received August 5, 2020.
  • Accepted March 23, 2021.
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Travis WD
    . Pathology of lung cancer. Clin Chest Med 2002; 23: 65–81. doi:10.1016/S0272-5231(03)00061-3
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lumb AB
    . Nunn's Applied Respiratory Physiology. 8th Edn. Amsterdam, Elsevier Health Sciences, 2016.
  3. ↵
    1. Ferlay J,
    2. Soerjomataram I,
    3. Dikshit R, et al.
    Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386. doi:10.1002/ijc.29210
    OpenUrlCrossRefPubMed
  4. ↵
    1. Chivima B
    . Lung cancer: a CPD article has improved Brenda Chivima's understanding of the care of patients with lung cancer. Nurs Stand 2015; 29: 61. doi:10.7748/ns.29.22.61.s50
    OpenUrl
  5. ↵
    1. Ali N,
    2. Lifford KJ,
    3. Carter B, et al.
    Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open 2015; 5: e008254.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Mitchell PD,
    2. Kennedy MP
    . Bronchoscopic management of malignant airway obstruction. Adv Ther 2014; 31: 512–538. doi:10.1007/s12325-014-0122-z
    OpenUrlPubMed
  7. ↵
    1. American Cancer Society
    . Cancer staging. www.cancer.org/treatment/understanding-your-diagnosis/staging.html Date last accessed: October 24, 2018.
  8. ↵
    1. Doll R,
    2. Peto R,
    3. Boreham J, et al.
    Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer 2005; 92: 426–429. doi:10.1038/sj.bjc.6602359
    OpenUrlPubMed
  9. ↵
    1. Peto R
    . Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321: 323–329. doi:10.1136/bmj.321.7257.323
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Parkin DM
    . 2. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer 2011; 105: S6. doi:10.1038/bjc.2011.475
    OpenUrlCrossRefPubMed
  11. ↵
    1. Mojic M,
    2. Takeda K,
    3. Hayakawa Y
    . The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci 2017; 19: 89. doi:10.3390/ijms19010089
    OpenUrlCrossRef
  12. ↵
    1. Castro F,
    2. Cardoso AP,
    3. Gonçalves RM, et al.
    Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 2018; 9: 847. doi:10.3389/fimmu.2018.00847
    OpenUrlCrossRefPubMed
  13. ↵
    1. Seif F,
    2. Khoshmirsafa M,
    3. Aazami H, et al.
    The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 2017; 15: 23. doi:10.1186/s12964-017-0177-y.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Melmed S
    2. Polonsky KS
    3. Larsen PR, et al.
    , eds. Williams Textbook of Endocrinology. 13th Edn. Amsterdam, Elsevier Health Sciences, 2015.
  15. ↵
    1. Krause CD,
    2. Lavnikova N,
    3. Xie J, et al.
    Preassembly and ligand-induced restructuring of the chains of the IFN-gamma receptor complex: the roles of Jak kinases, Stat1 and the receptor chains. Cell Res 2006; 16: 55–69. doi:10.1038/sj.cr.7310008
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kulling PM
    2. Olson KC
    3. Hamele CE R., et al.
    Dysregulation of the IFN-gamma-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 2018; 13: e0193429. doi:10.1371/journal.pone.0193429
    OpenUrl
  17. ↵
    1. Zaidi MR,
    2. Merlino G
    . The two faces of interferon-gamma in cancer. Clin Cancer Res 2011; 17: 6118–6124. doi:10.1158/1078-0432.CCR-11-0482
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Bernabei P,
    2. Coccia EM,
    3. Rigamonti L, et al.
    Interferon-γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 2001; 70: 950–960.
    OpenUrlPubMed
  19. ↵
    1. Rettino A,
    2. Clarke NM
    . Genome-wide identification of IRF1 binding sites reveals extensive occupancy at cell death associated genes. J Carcinog Mutagen 2013; S6: 1–10. 10.4172/2157-2518.S6-009.
    OpenUrl
  20. ↵
    1. Gao Y,
    2. Yang J,
    3. Cai Y, et al.
    IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer 2018; 143: 931–943. doi:10.1002/ijc.31357
    OpenUrl
  21. ↵
    1. Shen J,
    2. Xiao Z,
    3. Zhao Q, et al.
    Anti-cancer therapy with TNFα and IFNγ: a comprehensive review. Cell Proliferation 2018; 51: e12441. doi:10.1111/cpr.12441
    OpenUrl
  22. ↵
    1. Mishra G P,
    2. Bagui M,
    3. Tamboli V, et al
    . Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv 2011: 863734. doi: 10.1155/2011/863734.
  23. ↵
    1. Laouini A,
    2. Jaafar-Maalej C,
    3. Limayem-Blouza I, et al
    . Preparation, characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol 2012; 1: 147–168.
    OpenUrlCrossRef
  24. ↵
    1. Alavi M,
    2. Karimi N,
    3. Safaei M
    . Application of various types of liposomes in drug delivery systems. Adv Pharm Bull 2017; 7: 3–9.
    OpenUrl
  25. ↵
    1. Joshi S,
    2. Hussain M T,
    3. Roces C B, et al
    . Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs. Int J Pharmaceut 2016; 514: 160–168.
    OpenUrl
  26. ↵
    1. Shi K,
    2. Li J,
    3. Cao Z, et al
    . A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin avβ3 for the treatment of melanoma. J Controlled Release 2015; 217: 138–150.
    OpenUrl
  27. ↵
    1. Li F,
    2. Li Q-H,
    3. Wang J-Y, et al.
    Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release 2012; 159: 261–270. 10.1016/j.jconrel.2011.12.023.
    OpenUrlPubMed
  28. ↵
    1. Tice RR,
    2. Agurell E,
    3. Anderson D, et al.
    Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206–221. doi:10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J
    OpenUrlCrossRefPubMed
    1. Anderson D,
    2. Dobrzyńska MM,
    3. Basaran N
    . Effect of various genotoxins and reproductive toxins in human lymphocytes and sperm in the Comet assay. Teratoge Carcinog Mutagen 1997; 17: 29–43. doi:10.1002/(SICI)1520-6866(1997)17:1<29::AID-TCM5>3.0.CO;2-H
    OpenUrl
  30. ↵
    1. Singh NP,
    2. Mccoy MT,
    3. Tice RR, et al.
    A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184–191. doi:10.1016/0014-4827(88)90265-0
    OpenUrlCrossRefPubMed
  31. ↵
    1. OECD
    . Test No. 489: In Vivo Mammalian Alkaline Comet Assay, 2016.
  32. ↵
    1. Najafzadeh M, Anderson D
    . The use of isolated peripheral lymphocytes and human whole blood in the comet assay. Protoc Exchange 2016; 5207.
  33. ↵
    1. Najafzadeh M,
    2. Normington C,
    3. Jacob BK, et al.
    DNA damage in healthy individuals and respiratory patients after treating whole blood in vitro with the bulk and nano forms of NSAIDs. Front Mol Biosci 2016; 3: 50.
    OpenUrl
  34. ↵
    1. Fenech M,
    2. Knasmueller S,
    3. Bolognesi C, et al.
    Molecular mechanisms by which in vivo exposure to exogenous chemical genotoxic agents can lead to micronucleus formation in lymphocytes in vivo and ex vivo in humans. Mutat Res Rev Mutat Res 2016; 770: 12–25. doi:10.1016/j.mrrev.2016.04.008
    OpenUrl
  35. ↵
    1. Fenech M
    . Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007; 2: 1084–1104. doi:10.1038/nprot.2007.77
    OpenUrlCrossRefPubMed
  36. ↵
    1. Fenech M,
    2. Kirsch-Volders M,
    3. Natarajan A, et al.
    Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 2011; 26: 125–132. doi:10.1093/mutage/geq052
    OpenUrlCrossRefPubMed
  37. ↵
    1. Bausinger J,
    2. Speit G
    . The impact of lymphocyte isolation on induced DNA damage in human blood samples measured by the comet assay. Mutagenesis 2016; 31: 567–572. doi:10.1093/mutage/gew021
    OpenUrlCrossRefPubMed
  38. ↵
    1. Chan LL-Y,
    2. Rice WL,
    3. Qiu J
    . Observation and quantification of the morphological effect of trypan blue rupturing dead or dying cells. PLoS One 2020; 15: e0227950.
    OpenUrl
  39. ↵
    1. Riss TL,
    2. Moravec RA,
    3. Niles AL, et al.
    Cell viability assays. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2016.
  40. ↵
    1. Henderson L,
    2. Wolfreys A,
    3. Fedyk J, et al.
    The ability of the Comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis 1998; 13: 89–94. doi:10.1093/mutage/13.1.89
    OpenUrlCrossRefPubMed
  41. ↵
    1. Das A,
    2. Banik NL,
    3. Ray SK
    . Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells. Neurochem Res 2009; 34: 87–101. doi:10.1007/s11064-008-9669-x
    OpenUrlCrossRefPubMed
  42. ↵
    1. Wu Y,
    2. Meitzler JL,
    3. Antony S, et al.
    Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A. Oncotarget 2016; 7: 68412–68433. doi:10.18632/oncotarget.12032
    OpenUrl
  43. ↵
    1. Razaghi A,
    2. Villacrés C,
    3. Jung V, et al.
    Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells. Exp cell Res 2017; 359: 20–29.doi:10.1016/j.yexcr.2017.08.014
    OpenUrl
  44. ↵
    1. Bozzuto G,
    2. Molinari A
    . Liposomes as nanomedical devices. Int J Nanomed 2015; 10: 975–999. doi:10.2147/IJN.S68861
    OpenUrl
  45. ↵
    1. Trif M,
    2. Craciunescu O
    . 12 Liposome as efficient system for intracellular delivery of bioactive molecules. Nanotechnol Funct Foods 2015; 191.
  46. ↵
    1. Cho YH,
    2. Kim YJ,
    3. Lee S, et al.
    Effects of the DNA repair inhibitors, cytosine arabinoside and 3-aminobenzamide, on the frequency of radiation-induced micronuclei, nuclear buds, and nucleoplasmic bridges. Genes Genomics 2020; 42: 673–680. doi:10.1007/s13258-020-00934-8
    OpenUrl
  47. ↵
    1. Luzhna L,
    2. Kathiria P,
    3. Kovalchuk O
    . Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyond. Front Genet 2013; 4: 131. doi:10.3389/fgene.2013.00131
    OpenUrlCrossRefPubMed
  48. ↵
    1. Proudlock R
    1. Doherty A,
    2. Bryce SM,
    3. Bemis JC
    . Chapter 6 – The In Vitro Micronucleus Assay. In: Proudlock R, ed. Genetic Toxicology Testing. Boston, Academic Press, 2016.
  49. ↵
    1. Li Y,
    2. Chen DH,
    3. Yan J, et al.
    Genotoxicity of silver nanoparticles evaluated using the Ames test and in vitro micronucleus assay. Mutat Res Genet Toxicol Environ Mutagen 2012; 745: 4–10. doi:10.1016/j.mrgentox.2011.11.010
    OpenUrl
  50. ↵
    1. De Saint Jean M,
    2. Brignole F,
    3. Bringuier AF, et al
    . Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40: 619–630.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Barenholz Y,
    2. Peer D
    . Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. J Control Release 2012; 160: 115–116.
    OpenUrlPubMed
Back to top
Email
Print
Citation Tools
Interferon-γ liposome: a new system to improve drug delivery in the treatment of lung cancer
Maysa Alhawamdeh, Mohammad Isreb, Abid Aziz, Badie K. Jacob, Diana Anderson, Mojgan Najafzadeh
ERJ Open Research Jul 2021, 7 (3) 00555-2020; DOI: 10.1183/23120541.00555-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

Subjects